Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model

Fig. 3

In vitro effects of Ad-ΔB and Ad-ΔB/TRAIL+Ad-ΔB/IL-12 on Hep3B and HuH7 human HCC cells and normal human liver (WRL68) cells. a Quantitative results of MTT assay showing the inhibitor effects on viability of Hep3B cells at 5 and 10 MOI (the multiplicity of infection) per virus; (b) Quantitative results of MTT assay showing the inhibitor effects on viability of HuH7 cells at 10 and 20 MOI per virus; and (c) Quantitative results of MTT assay showing the inhibitor effects on viability of WRL68 cells at 50 MOI per virus. Data are represented as mean ± SE. d Representatives of semi-quantitative assessment of cytotoxic potency by crystal violet cytopathic effect assay on Hep3B cells (left panel), HuH7 cells (middle panel), and WRL68 cells (right panel) at indicated MOIs. Ad-ΔB = non-armed control oncolytic adenovirus; Ad-ΔB/TRAIL+Ad-ΔB/IL-12 (or Ad-ΔB/TRAIL+IL-12) = combined therapy with two oncolytic adenoviruses encoding human TRAIL and IL-12 genes, respectively

Back to article page